Anti-Human PD-L1 Polyclonal Antibody (HV974014)

Name: Anti-Human PD-L1 Polyclonal Antibody
Brand: abinScience
SKU: HV974014
Price: 168 USD
Availability: InStock

데이터시트 제품 공유 정보 복사

가격(USD):

사양:

50ug
100ug

수량:

문의하기

개요
이미지
참고 문헌
데이터시트
SDS

개요

카탈로그 번호

HV974014

설명

Anti-CD274/PD-L1/B7-H1 Polyclonal Antibody (HV974014) is a rabbit polyclonal antibody detecting B7-H1 in ELISA, IHC, WB. Suitable for Human.

Highlights

●Affinity Purified — Minimal background and high purity for reliable results.
●Multi-Application — Validated across multiple applications.

종 반응성

Human

응용 분야

ELISA, IHC, WB

숙주 종

Rabbit

클론성

Polyclonal

이소타입

IgG

면역원

E. coli - derived recombinant Human CD274/PD-L1/B7-H1 (Phe19-Arg238).

타겟

B7 homolog 1, B7-H1, B7H1, CD274, PD-L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, PDL1, Programmed cell death 1 ligand 1, Programmed death ligand 1

내독소 수준

Please contact with the lab for this information.

순도

>90% as determined by SDS-PAGE.

정제

Purified by antigen affinity column.

등록번호

Q9NZQ7

형태

Liquid

저장 완충액

0.01M PBS, pH 7.4, 50% glycerol, 0.05% Proclin 300.

데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요.

제품 사용 정보

응용 분야	희석
ELISA	1:5000-1:20000
IHC	1:50-1:500
WB	1:500-1:2000

안정성 및 저장

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

배경

Programmed cell death 1 ligand 1 (CD274/PD-L1) is a ~33 kDa protein. Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis. CD274 is the therapeutic target of atezolizumab (Tecentriq) and durvalumab (Imfinzi).

1. Freeman, GJ. et al. (2000) The Journal of experimental medicine 192, 1027-34. PMID: 11015443

2. Mezzadra, R. et al. (2017) Nature 549, 106-110. PMID: 28813410

3. Burr, ML. et al. (2017) Nature 549, 101-105. PMID: 28813417

4. Huang, X. et al. (2019) Cancer immunology research 7, 1580-1590. PMID: 31399419

5. Kennedy, A. et al. (2023) The EMBO journal 42, e111556. PMID: 36727298

6. Dong, H. et al. (1999) Nature medicine 5, 1365-9. PMID: 10581077

7. Hou, J. et al. (2020) Nature cell biology 22, 1264-1275. PMID: 32929201

참고사항

For research use only.

이미지

참고 문헌

데이터시트